The 2020 Tourette Syndrome pipeline report presents a comprehensive overview of the research and development of Tourette Syndrome drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Two drugs in Pre-clinical phase, one drug in Phase 1, five drugs in Phase 2 and two drugs in Phase 3.
As of February 2020, the Tourette Syndrome pipeline remains robust with 11 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Tourette Syndrome treatment. Diverse types of targeted therapies are being explored through clinical trials including Alpha 2A adrenergic receptor agonist; Cannabinoid receptor modulators; Dopamine D1 receptor antagonist; dopamine inhibitor; GABA-A receptor antagonist; gamma-aminobutyric acid (GABA) inhibitor; monoacylglycerol lipase inhibitor; noradrenaline transporters; Vesicular monoamine transporter 2 inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Tourette Syndrome drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
Publisher Expertise
The publisher's online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
Scope:
Tourette Syndrome pipeline companies included in the report are: Abide Therapeutics, Adeptio Pharmaceuticals Ltd, Asarina Pharma AB, Catalyst Pharmaceuticals Inc, Emalex Biosciences Inc, KemPharm Inc, Neurocrine Biosciences Inc, SOM Biotech SL, Teva Pharmaceutical Industries Ltd, Therapix Biosciences Ltd.
Tourette Syndrome pipeline drugs profiled in the report include: (amfetamine + guanfacine), alpha-dihydrotetrabenazine, sepranolone (UC1010), CPP-115, ecopipam (PSYRX 101), ABX-1431, valbenazine (NBI-98854), bevantolol (SOM-3355), deutetrabenazine (SD-809), THX-120, THX-110 (dronabinol + palmitoylethanolamide).
As of February 2020, the Tourette Syndrome pipeline remains robust with 11 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Tourette Syndrome treatment. Diverse types of targeted therapies are being explored through clinical trials including Alpha 2A adrenergic receptor agonist; Cannabinoid receptor modulators; Dopamine D1 receptor antagonist; dopamine inhibitor; GABA-A receptor antagonist; gamma-aminobutyric acid (GABA) inhibitor; monoacylglycerol lipase inhibitor; noradrenaline transporters; Vesicular monoamine transporter 2 inhibitor.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Tourette Syndrome drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
Publisher Expertise
The publisher's online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
Scope:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Tourette Syndrome development
- Tourette Syndrome pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Tourette Syndrome pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Tourette Syndrome pipeline candidates included
- Business overview and snapshot of all companies involved in Tourette Syndrome pipeline are included
- Latest market and pipeline developments are provided in the report
Tourette Syndrome pipeline companies included in the report are: Abide Therapeutics, Adeptio Pharmaceuticals Ltd, Asarina Pharma AB, Catalyst Pharmaceuticals Inc, Emalex Biosciences Inc, KemPharm Inc, Neurocrine Biosciences Inc, SOM Biotech SL, Teva Pharmaceutical Industries Ltd, Therapix Biosciences Ltd.
Tourette Syndrome pipeline drugs profiled in the report include: (amfetamine + guanfacine), alpha-dihydrotetrabenazine, sepranolone (UC1010), CPP-115, ecopipam (PSYRX 101), ABX-1431, valbenazine (NBI-98854), bevantolol (SOM-3355), deutetrabenazine (SD-809), THX-120, THX-110 (dronabinol + palmitoylethanolamide).
Table of Contents
1. Table of Contents
2. Executive Summary
3. Companies Active in Pipeline Development
4. Active Pipeline Drug Details, 2020
6. Appendix
Companies Mentioned
- Abide Therapeutics
- Adeptio Pharmaceuticals Ltd
- Asarina Pharma AB
- Catalyst Pharmaceuticals Inc
- Emalex Biosciences Inc
- KemPharm Inc
- Neurocrine Biosciences Inc
- SOM Biotech SL
- Teva Pharmaceutical Industries Ltd
- Therapix Biosciences Ltd
